Int J Thyroidol.  2021 Nov;14(2):87-92. 10.11106/ijt.2021.14.2.87.

Completion Thyroidectomy

• Cheon Y
• Shin SC
• Lee BJ

• KMID: 2522912
• DOI: http://doi.org/10.11106/ijt.2021.14.2.87

Abstract

Completion thyroidectomy is defined as surgical removal of the remnant thyroid tissue after resection of the thyroid gland. The frequency of completion thyroidectomy varies among researchers, but is estimated to be about 5-45%. Completion thyroidectomy may cause complications due to the presence of inflammation, adhesions, swelling, and scars at the surgical site due to the initial surgery. There is still controversy over the indications and timing of completion thyroidectomy. In this review, we would like to summarize the changes in indications for completion thyroidectomy and review the literature on its necessity.

Keyword

Thyroid cancer; Completion thyroidectomy; Operation

Reference

References

1. Kuo LE, Angell TE, Pandian TK, Moore AL, Alexander EK, Barletta JA, et al. 2021; Completion thyroidectomy is less common following updated 2015 American Thyroid Association guidelines. Ann Surg Oncol. 28(1):484–91. DOI: 10.1245/s10434-020-08709-x. PMID: 32583197.

2. Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2018. Ministry of Health and Welfare;2020.

3. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. 2014; Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 260(4):601–5. discussion 5–7. DOI: 10.1097/SLA.0000000000000925. PMID: 25203876. PMCID: PMC4532384.

4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2016; 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26(1):1–133. DOI: 10.1089/thy.2015.0020. PMID: 26462967. PMCID: PMC4739132.

5. National Comprehensive Cancer Network (NCCN). 2021. NCCN clinical practive guidelines in oncology: thyroid carcinoma. Available from: http://www.nccn.org/professionals/physician_gls/default.aspx. cited June 22, 2021.

6. Yi KH, Lee EK, Kang H-C, Koh Y, Kim SW, Kim IJ, et al. 2016; 2016 revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol. 9(2):59–126. DOI: 10.11106/ijt.2016.9.2.59.

7. Kim TY, Shong YK. 2017; Active surveillance of papillary thyroid microcarcinoma: a mini-review from Korea. Endocrinol Metab (Seoul). 32(4):399–406. DOI: 10.3803/EnM.2017.32.4.399. PMID: 29271613. PMCID: PMC5745193.

8. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, et al. 2014; Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 81 Suppl 1:1–122. DOI: 10.1111/cen.12515. PMID: 24989897.

9. Murthy SP, Balasubramanian D, Subramaniam N, Nair G, Babu MJC, Rathod PV, et al. 2018; Prevalence of adverse pathological features in 1 to 4 cm low-risk differentiated thyroid carcinoma. Head Neck. 40(6):1214–8. DOI: 10.1002/hed.25099. PMID: 29417654.

10. Eroglu A, Berberoglu U, Buruk F, Yildirim E. 1995; Completion thyroidectomy for differentiated thyroid carcinoma. J Surg Oncol. 59(4):261–6. discussion 6–7. DOI: 10.1002/jso.2930590413. PMID: 7630175.

11. Makay O, Unalp O, Icoz G, Akyildiz M, Yetkin E. 2006; Completion thyroidectomy for thyroid cancer. Acta Chir Belg. 106(5):528–31. DOI: 10.1080/00015458.2006.11679945. PMID: 17168263.

12. Varaldo E, Ansaldo GL, Assalino M, Massobrio A, Torre GC, Borgonovo G. 2012; Completion thyroidectomy for differentiated thyroid cancer (results in a consecutive series of 68 patients). Acta Chir Belg. 112(1):40–3. DOI: 10.1080/00015458.2012.11680793. PMID: 22442908.

13. Shaha AR, Michael Tuttle R. 2019; Completion thyroidectomy-indications and complications. Eur J Surg Oncol. 45(7):1129–31. DOI: 10.1016/j.ejso.2019.03.028. PMID: 30935727.

14. Sawant R, Hulse K, Sohrabi S, Yeo JCL, Pal K, Gibb FW, et al. 2019; The impact of completion thyroidectomy. Eur J Surg Oncol. 45(7):1171–4. DOI: 10.1016/j.ejso.2019.03.018. PMID: 30910458.

15. Hardman JC, Smith JA, Nankivell P, Sharma N, Watkinson JC. 2015; Re-operative thyroid surgery: a 20-year prospective cohort study at a tertiary referral centre. Eur Arch Otorhinolaryngol. 272(6):1503–8. DOI: 10.1007/s00405-014-3068-5. PMID: 24816833.

16. Vaiman M, Nagibin A, Olevson J. 2010; Complications in primary and completed thyroidectomy. Surg Today. 40(2):114–8. DOI: 10.1007/s00595-008-4027-9. PMID: 20107949.

17. Lefevre JH, Tresallet C, Leenhardt L, Jublanc C, Chigot JP, Menegaux F. 2007; Reoperative surgery for thyroid disease. Langenbecks Arch Surg. 392(6):685–91. DOI: 10.1007/s00423-007-0201-6. PMID: 17593385.

18. Mirghani H, Altedlawi Albalawi IA 2nd. 2020; The ongoing debate regarding completion thyroidectomy versus primary thyroid surgery for low and intermediate differentiated thyroid carcinoma: a meta-analysis. Cureus. 12(12):e12033. DOI: 10.7759/cureus.12033. PMID: 33329985. PMCID: PMC7734888.

19. Gulcelik MA, Dogan L, Akgul GG, Guven EH, Ersoz Gulcelik N. 2018; Completion thyroidectomy: safer than thought. Oncol Res Treat. 41(6):386–90. DOI: 10.1159/000487083. PMID: 29734197.

20. Walgenbach S, Junginger T. 2002; Is the timing of completion thyroidectomy for differentiated thyroid carcinoma prognostic significant? Zentralbl Chir. 127(5):435–8. DOI: 10.1055/s-2002-31973. PMID: 12058304.

21. Glockzin G, Hornung M, Kienle K, Thelen K, Boin M, Schreyer AG, et al. 2012; Completion thyroidectomy: effect of timing on clinical complications and oncologic outcome in patients with differentiated thyroid cancer. World J Surg. 36(5):1168–73. DOI: 10.1007/s00268-012-1484-5. PMID: 22366982.

22. Bin Saleem R, Bin Saleem M, Bin Saleem N. 2018; Impact of completion thyroidectomy timing on post-operative complications: a systematic review and meta-analysis. Gland Surg. 7(5):458–65. DOI: 10.21037/gs.2018.09.03. PMID: 30505767. PMCID: PMC6234247.

23. Guo MY, Wiseman JJ, Wiseman SM. 2021; Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review. Expert Rev Anticancer Ther. 21(2):205–20. DOI: 10.1080/14737140.2021.1850280. PMID: 33176520.

24. Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Shen WT, Gosnell JE, et al. 2017; Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Surgery. 161(1):127–33. DOI: 10.1016/j.surg.2016.05.056. PMID: 27855968.

25. Kluijfhout WP, Pasternak JD, Lim J, Kwon JS, Vriens MR, Clark OH, et al. 2016; Frequency of high-risk characteristics requiring total thyroidectomy for 1-4 cm well-differentiated thyroid cancer. Thyroid. 26(6):820–4. DOI: 10.1089/thy.2015.0495. PMID: 27083216.

26. Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. 2015; Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 100(4):1529–36. DOI: 10.1210/jc.2014-4332. PMID: 25642591. PMCID: PMC4399282.

27. Liu J, Zhang Z, Huang H, Xu S, Liu Y, Liu S, et al. 2019; Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: a single-institution matched-pair analysis. Oral Oncol. 90:17–22. DOI: 10.1016/j.oraloncology.2019.01.010. PMID: 30846171.

28. Riju J, Thomas S, Anila KR. 2019; Completion thyroidectomy in differentiated thyroid malignancy-a prospective analysis. Indian J Surg Oncol. 10(1):130–4. DOI: 10.1007/s13193-018-0845-4. PMID: 30948887. PMCID: PMC6414589.

29. Ibrahim B, Forest VI, Hier M, Mlynarek AM, Caglar D, Payne RJ. 2015; Completion thyroidectomy: predicting bilateral disease. J Otolaryngol Head Neck Surg. 44:23. DOI: 10.1186/s40463-015-0076-4. PMID: 26077153. PMCID: PMC4480506.

30. Li YJ, Wang YZ, Yi ZB, Chen LL, Zhou XD. 2015; Comparison of completion thyroidectomy and primary total surgery for differentiated thyroid cancer: a meta-analysis. Oncol Res Treat. 38(10):528–31. DOI: 10.1159/000440690. PMID: 26451702.

31. Al-Qurayshi Z, Shama MA, Randolph GW, Kandil E. 2017; Minimal extrathyroidal extension does not affect survival of well-differentiated thyroid cancer. Endocr Relat Cancer. 24(5):221–6. DOI: 10.1530/ERC-16-0509. PMID: 28249964.

32. Lang BH, Shek TW, Wan KY. 2017; The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4 cm: implications for completion thyroidectomy following lobectomy. Clin Endocrinol (Oxf). 86(2):236–42. DOI: 10.1111/cen.13165. PMID: 27467318.

33. Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, et al. 2012; Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 151(4):571–9. DOI: 10.1016/j.surg.2011.08.016. PMID: 22001636.

34. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. 2014; Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 38(1):68–79. DOI: 10.1007/s00268-013-2224-1. PMID: 24081532.

35. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. 2009; Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 19(5):451–7. DOI: 10.1089/thy.2008.0392. PMID: 19281429.